Market News

Barclays initiates coverage of Tilray, Cronos and Canopy Growth


Barclays analyst Guarav Jain on Thursday initiated coverage of three cannabis stocks but said their businesses are limited by the relatively small size of the legal market in Canada. Barclays launched overage of Tilray

and Cronos

with an underweight rating and price targets of $10 and $5.50 respectively. Barclays also initiated coverage of Canopy Growth

with a price target of $14 and a equal weight rating. Canada will account for about 30% of Canopy’s and Tilray’s operating enterprise value, and about 40% for Cronos. “The rest of their enterprise value is attributable to optionality in the U.S. market” through alliances with U.S.-based multi-state cannabis operators, he said. “Canadian companies cannot directly invest in the US market. They are entering into structured transactions with U.S. multi-state operators that would convert into minority stakes upon U.S. federal legalization. We think the benefit of these deals accrues to the shareholders of MSOs rather than those of the Canadian companies.”

Here are Thursday’s biggest analyst calls of the day: Amazon, Deere, Square, Uber & more

Previous article

John Malone says there’s a misguided ‘land rush’ in stocks right now akin to late ’90s bubble

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Market News